<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transpl Int</journal-id><journal-id journal-id-type="iso-abbrev">Transpl Int</journal-id><journal-id journal-id-type="pmc-domain-id">4159</journal-id><journal-id journal-id-type="pmc-domain">transinter</journal-id><journal-id journal-id-type="publisher-id">Transpl Int</journal-id><journal-title-group><journal-title>Transplant International</journal-title></journal-title-group><issn pub-type="ppub">0934-0874</issn><issn pub-type="epub">1432-2277</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10713790</article-id><article-id pub-id-type="pmcid-ver">PMC10713790.1</article-id><article-id pub-id-type="pmcaid">10713790</article-id><article-id pub-id-type="pmcaiid">10713790</article-id><article-id pub-id-type="pmid">38089004</article-id><article-id pub-id-type="doi">10.3389/ti.2023.11962</article-id><article-id pub-id-type="publisher-id">11962</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Health Archive</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Measurement of the Immunosuppressant Possession Ratio by Transplant Clinical Pharmacists Captures a Non-Adherence Associated With Antibody-Mediated Rejection</article-title><alt-title alt-title-type="left-running-head">Chambord et al.</alt-title><alt-title alt-title-type="right-running-head">Immunosuppressant Possession Ratio to Diagnose Non-Adherence</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chambord</surname><given-names initials="J">J&#233;r&#233;my</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2419367/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chauveau</surname><given-names initials="B">Bertrand</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Djabarouti</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vignaud</surname><given-names initials="J">Jean</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taton</surname><given-names initials="B">Benjamin</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moreau</surname><given-names initials="K">Karine</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1504268/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Visentin</surname><given-names initials="J">Jonathan</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Merville</surname><given-names initials="P">Pierre</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xuereb</surname><given-names initials="F">Fabien</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Couzi</surname><given-names initials="L">Lionel</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/199532/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Service de Pharmacie</institution>, <institution>Centre Hospitalier Universitaire de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Service d&#8217;Anatomopathologie</institution>, <institution>Centre Hospitalier Universitaire de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>CNRS-UMR 5164 ImmunoConcEpT</institution>, <institution>Universit&#233; de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>INSERM U1312 BRIEC</institution>, <institution>Universit&#233; de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Service de N&#233;phrologie</institution>, <institution>Transplantation</institution>, <institution>Dialyse, Aph&#233;r&#232;se</institution>, <institution>Centre Hospitalier Universitaire de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Service d&#8217;Immunologie et Immunog&#233;n&#233;tique</institution>, <institution>Centre Hospitalier Universitaire de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>INSERM U1034</institution>, <institution>Universit&#233; de Bordeaux</institution>, <addr-line>Bordeaux</addr-line>, <country>France</country>
</aff><author-notes><corresp id="c001">*Correspondence: J&#233;r&#233;my Chambord, <email>jeremy.chambord@chu-bordeaux.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>36</volume><issue-id pub-id-type="pmc-issue-id">427418</issue-id><elocation-id>11962</elocation-id><history><date date-type="received"><day>25</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>11</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>12</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-29 01:25:23.487"><day>29</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Chambord, Chauveau, Djabarouti, Vignaud, Taton, Moreau, Visentin, Merville, Xuereb and Couzi.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chambord, Chauveau, Djabarouti, Vignaud, Taton, Moreau, Visentin, Merville, Xuereb and Couzi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ti-36-11962.pdf"/><abstract><p>Our objective was to calculate an immunosuppressant possession ratio (IPR) to diagnose non-adherence at the time of antibody-mediated rejection (ABMR). IPR was defined as the ratio of number of pills collected at the pharmacy to the number of pills prescribed over a defined period. In a first cohort of 91 kidney transplant recipients (KTRs), those with an IPR &lt; 90% had more frequently a tacrolimus through level coefficient of variation &gt;30% than patients with an IPR = 100% (66.7% vs. 29.4%, <italic toggle="yes">p</italic> = 0.05). In a case-control study, 26 KTRs with ABMR had lower 6&#160;months IPRs than 26 controls (76% vs. 99%, <italic toggle="yes">p</italic> &lt; 0.001). In KTRs with ABMR, non-adherence was more often diagnosed by a 6&#160;months IPR &lt; 90% than by clinical suspicion (73.1% vs 30.8%, <italic toggle="yes">p</italic> = 0.02). In the multivariable analysis, only <italic toggle="yes">de novo</italic> DSA and 6&#160;months IPR &lt; 90% were independently associated with ABMR, whereas clinical suspicion was not (odds ratio, 4.73; 95% CI, 1.17&#8211;21.88; <italic toggle="yes">p</italic> = 0.03; and odds ratio, 6.34; 95% CI, 1.73&#8211;25.59; <italic toggle="yes">p</italic> = 0.007, respectively). In summary, IPR &lt; 90% is a quantifiable tool to measure immunosuppressant non-adherence. It is better associated with ABMR than clinical suspicion of non-adherence.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="TI_ti-2023-11962_wc_abs.jpg"/>
</p></abstract><kwd-group><kwd>kidney transplantation</kwd><kwd>clinical pharmacist</kwd><kwd>adherence</kwd><kwd>immunosuppresant possession ratio</kwd><kwd>antibody-mediated rejection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The prevalence of non-adherence to immunosuppressants in renal transplant recipients is between 20%&#8211;35% in adults [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>]. This is a continuous process which increases during the first 2&#160;years post-transplantation [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>], and is associated with <italic toggle="yes">de novo</italic> donor-specific antibodies occurrence (DSA) [<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B8" ref-type="bibr">8</xref>], antibody-mediated rejection (ABMR) [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>], T-cell mediated rejection [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>], and graft loss [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>]. Proactive interventions to improve adherence are essential for the prevention of allograft loss. However, before designing a suitable multi-dimensional intervention, the key question is how immunosuppressant non-adherence can be diagnosed prospectively [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Subjective methods to assess non-adherence include clinical suspicion and self-administered questionnaires. Suspicion by the clinician of medication non-adherence underestimates this phenomenon and is frequently influenced by a poor outcome or non-adherence to follow-up [<xref rid="B18" ref-type="bibr">18</xref>]. Self-reported measurement of medication non-adherence is easily distorted by patients, explaining why its ability to predict rejection and graft loss is equivocal [<xref rid="B19" ref-type="bibr">19</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>]. Objective methods for the measurement of non-adherence include calcineurin inhibitor trough levels and electronic monitoring. Both low calcineurin inhibitor trough levels [<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>] and intra-patient variability of tacrolimus are associated with <italic toggle="yes">de novo</italic> DSA, rejection, and graft loss [<xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B31" ref-type="bibr">31</xref>]. However, interactions with a drug or food can give a false impression of non-adherence. The ability of electronic monitoring to measure non-adherence to immunosuppressants is also debated [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>]. In addition, this tool is very costly and restrictive, which could prevent its implementation in a clinical setting.</p><p>Therefore, transplant physicians do not yet have an objective and easily usable method for measuring non-adherence to immunosuppressants [<xref rid="B1" ref-type="bibr">1</xref>]. The Immunosuppressant Possession Ratio (IPR) is the number of therapeutic units collected at the pharmacy divided by the number of therapeutic units prescribed over the same period of time [<xref rid="B12" ref-type="bibr">12</xref>]. Retrospective studies using Medicare data in the United States reported that low IPRs were associated with graft failure [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. In these studies, IPR thresholds used to determine non-adherence varied between 80% and 99%. In France, the rate of prescription refill can be easily retrieved through pharmacy management software. No special authorization is required.</p><p>The objectives of this study were: 1) to test the feasibility of prospectively calculating the IPR in a first cohort of kidney transplant recipients (KTR), 2) to determine its association with other markers of non-adherence, 3) to determine a standardized period for its calculation, 4) to analyze whether the IPR-based non-adherence diagnosis was associated with ABMR in a second cohort of KTR, and 5) to compare the IPR-based non-adherence diagnosis with our standard method based on clinical suspicion.</p></sec><sec sec-type="patients|methods" id="s2"><title>Patients and Methods</title><sec id="s2-1"><title>Study Design and Patients</title><sec id="s2-1-1"><title>First Prospective Cohort</title><p>We conducted a non-interventional study at Bordeaux University Hospital between May and July 2018 on a first cohort to test the feasibility of prospectively calculating the IPR. Ninety-one consecutive kidney transplant recipients coming for an outpatient visit between 8 and 16&#160;months post-transplantation were included (<xref rid="F1" ref-type="fig">Figure 1A</xref>). During this inclusion visit, the following patient information was collected: treatments doses, prescription refills and hospitalization stays since transplantation for calculating the IPR, calcineurin inhibitor trough levels, missed outpatient visits, and patient-reported drug side effects. Patients were also asked if they had forgotten to take their medication at least once since transplantation. No pill count was carried out.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Description of the two Cohorts. Study design of the first prospective Cohort 1 <bold>(A)</bold>. Flow chart of the retrospective Cohort 2 <bold>(B)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ti-36-11962-g001.jpg"/></fig></sec><sec id="s2-1-2"><title>Second Retrospective Cohort</title><p>We tested the association of IPR with the occurrence of clinically apparent histological ABMR (hABMR) in a second retrospective cohort of patients. Between January and December 2020, 451 kidney transplant biopsies were performed at our institution. We excluded 229 biopsies performed during the first 12&#160;months post-transplantation, because the calculation of the IPR required a 6 or 12&#160;months period. Among the 222 remaining for-cause biopsies, we identified 27 patients with a diagnosis of clinical hABMR and 108 with interstitial fibrosis and tubular atrophy (IFTA) without additional specific lesion. The IPR was not available for one ABMR patient because this patient used many community pharmacies and we were not able to recover prescription refills from all of them. The IPR was then compared between the clinical hABMR group (<italic toggle="yes">n</italic> = 26) and an IFTA control group of 26 patients that were matched 1:1 for age and year of transplantation (<xref rid="F1" ref-type="fig">Figure 1B</xref>). In this cohort we compared the IPR-based non-adherence diagnosis with our standard method based on clinical suspicion.</p><p>The study was approved by the local Ethics Committee and conducted in accordance with the Declaration of Helsinki. Our clinical database had a French CNIL final agreement, decision 2009-413, n&#176; 1357154, 2 July 2009.</p></sec></sec><sec id="s2-2"><title>Measurement of the Immunosuppressant Possession Ratio</title><p>IPR since transplantation was calculated by two transplant clinical pharmacists, as follows: data related to immunosuppressant prescriptions such as dosage and quantity were collected from our patient medical records (R@N); data related to prescription refills and patient dispensing were provided by the patients&#8217; pharmacists using their community pharmacy management software. IPR was then calculated according to the following formula: IPR = (number of pills collected at the pharmacy/number of pills prescribed over the study period) &#215; 100. Importantly, IPR was calculated taking into account hospitalization stays, during which the patients did not use their personal medication supply (<xref rid="F2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Measurement of the immunosuppressant possession ratio (IPR).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ti-36-11962-g002.jpg"/></fig><p>The most frequently used drug for calculating IPR was mycophenolate, in 71 patients (78.0%) in Cohort 1 and 34 patients (65.4%) in Cohort 2, because its dose did not change frequently. If the mycophenolate was discontinued, steroids, everolimus, azathioprine and tacrolimus were used in 17 patients (18.7%), 1 (1.1%), 1 (1.1%) and 1 patient (1.1%), in Cohort 1, respectively, and steroids, azathioprine, tacrolimus and cyclosporine were used in 14 patients (26.9%), 1 (1.9%), 2 (3.8%) and 1 patient (1.9%) in Cohort 2, respectively.</p></sec><sec id="s2-3"><title>Measurement of Drug Exposure: Calcineurin Inhibitor Trough Levels</title><p>Intra-patient variabilities of tacrolimus and cyclosporine were calculated using the coefficient of variation (CV<sub>TAC</sub>; CV<sub>CsA</sub>). The CV was calculated using the following formula: (standard deviation/mean trough levels of tacrolimus or cyclosporine) &#215; 100. The mean and standard deviation were calculated using all available plasma concentrations. Patients with a CV<sub>TAC</sub> &gt; 30% were considered to have experienced varying levels of exposure to tacrolimus and were described as being at higher risk of <italic toggle="yes">de novo</italic> DSA and graft loss [<xref rid="B30" ref-type="bibr">30</xref>]. In cohort 2, we also measured the last tacrolimus and cyclosporine trough level because values &lt;5&#160;ng/mL, are known to be associated with higher <italic toggle="yes">de novo</italic> DSA incidence [<xref rid="B26" ref-type="bibr">26</xref>].</p></sec><sec id="s2-4"><title>Clinical Suspicion of Non-Adherence</title><p>Clinical suspicion of non-adherence was documented by clinic staff and registered in the patients&#8217; medical records.</p></sec><sec id="s2-5"><title>Definition of Histological ABMR</title><p>The 222 for-cause biopsies performed were reviewed according to the Banff 2019 classification [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>We used the term &#8220;histological ABMR&#8221; (hABMR) proposed by Senev et al. [<xref rid="B37" ref-type="bibr">37</xref>] for cases that met the first two Banff 2019 criteria for histology of ABMR. Criterion 1 included one or more of the following lesions: glomerulitis (g), peritubular capillaritis (ptc), arteritis, or thrombotic microangiopathy. Criterion 2 included a microvascular inflammation score (g+ptc) &#8805; 2 and/or linear C4d staining on peritubular capillaries [<xref rid="B16" ref-type="bibr">16</xref>]. This definition of histological ABMR was made regardless of the third criterion (serological evidence of DSA). Cases with histological ABMR could then be anti-HLA DSA positive or without detectable anti-HLA DSA.</p></sec><sec id="s2-6"><title>Identification of Anti-HLA Donor-Specific Antibodies</title><p>Sera were tested at the time of each biopsy with single-antigen flow beads assays (SAFB) (One Lambda, Inc., Canoga Park, CA) in accordance with the manufacturer&#8217;s recommendations for routine assay use, with ethylenediaminetetraacetic acid in order to avoid the complement interference phenomenon [<xref rid="B38" ref-type="bibr">38</xref>&#8211;<xref rid="B40" ref-type="bibr">40</xref>]. The SAFB were acquired on a Luminex 100<sup>&#174;</sup> analyzer (Luminex, Austin, TX). Mean fluorescence intensity (MFI) values were normalized using the baseline formula (Fusion<sup>&#174;</sup> software, One Lambda, Inc.). The positivity threshold was set at MFI &#8805; 500.</p></sec><sec id="s2-7"><title>Statistical Analysis</title><p>The groups were compared using Fisher&#8217;s exact test or McNemar&#8217;s test for the qualitative variables and Student&#8217;s t-test and the Mann&#8211;Whitney test for the quantitative variables. The relationship between different computations of the IPR were assessed with Spearman&#8217;s correlation (rho). Patient characteristics and pharmacokinetics data were expressed as medians with the interquartile range (IQR). A <italic toggle="yes">p-</italic>value &#8804; 0.05 was considered to represent statistical significance. Factors associated with hABMR in cohort 2 were identified using logistic regression. Risk factors with a <italic toggle="yes">p-</italic>value lower than 0.2 in the univariable analysis were included in two multivariable models that were simplified by iterative backward elimination, only keeping the covariables with a <italic toggle="yes">p</italic>-value below or equal to 0.05. A ROC curve analysis was performed to identify an optimal threshold of IPR to predict hABMR. Finally, we used the net reclassification improvement (NRI) to compare the clinical utility of the 6&#160;months IPR &lt; 90% with the clinical suspicion of non-adherence, for the hABMR prediction [<xref rid="B41" ref-type="bibr">41</xref>]. The GraphPad Prism v8<sup>&#174;</sup> software was used for statistical analyses.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Prospective Calculation of the Immunosuppressant Possession Ratio</title><p>The baseline characteristics of the 91 patients of the first cohort at inclusion are presented in <xref rid="T1" ref-type="table">Table 1</xref>. All patients received tacrolimus, and 84 (92.3%) were treated with an extended-release formulation (<xref rid="T1" ref-type="table">Table 1</xref>). Tacrolimus was given in association with mycophenolate in 71 patients (78.0%), everolimus in 12 patients (13.2%) and azathioprine in 2 patients (2.2%). Steroids were given to 62 patients (68.1%).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Patients&#8217; characteristics in prospective cohort 1, according to the immunosuppressant possession ratio.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 91)</th><th align="center" rowspan="1" colspan="1">IPR &lt; 90% (<italic toggle="yes">n</italic> = 9)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> (vs. IPR = 100%)</th><th align="center" rowspan="1" colspan="1">IPR = 90&#8211;94% (<italic toggle="yes">n</italic> = 6)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> (vs. IPR = 100%)</th><th align="center" rowspan="1" colspan="1">IPR = 95&#8211;99% (<italic toggle="yes">n</italic> = 25)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> (vs. IPR = 100%)</th><th align="center" rowspan="1" colspan="1">IPR = 100% (<italic toggle="yes">n</italic> = 51)</th></tr></thead><tbody valign="top"><tr><td colspan="9" align="left" rowspan="1">Baseline characteristics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Age (years, IQR)</td><td align="center" rowspan="1" colspan="1">57 (47&#8211;65)</td><td align="center" rowspan="1" colspan="1">54 (35&#8211;71.5)</td><td align="center" rowspan="1" colspan="1">0.91</td><td align="center" rowspan="1" colspan="1">60.5 (52&#8211;70.3)</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">60 (49&#8211;64.5)</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">55 (43&#8211;65)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female (%)</td><td align="center" rowspan="1" colspan="1">29 (31.9%)</td><td align="center" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">8 (32.0%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">17 (33.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Time since transplantation (months, IQR)</td><td align="center" rowspan="1" colspan="1">12.7 (10.2&#8211;15.6)</td><td align="center" rowspan="1" colspan="1">13.2 (11.4&#8211;15.5)</td><td align="center" rowspan="1" colspan="1">0.68</td><td align="center" rowspan="1" colspan="1">17.1 (13.4&#8211;17.9)</td><td align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" rowspan="1" colspan="1">12.1 (10.1&#8211;15.5)</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">12.7 (9.6&#8211;15.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&#8805;2 transplantations (%)</td><td align="center" rowspan="1" colspan="1">13 (14.3%)</td><td align="center" rowspan="1" colspan="1">2 (22.2%)</td><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">1 (4.0%)</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">9 (17.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hemodialysis (%)</td><td align="center" rowspan="1" colspan="1">63 (69.2%)</td><td align="center" rowspan="1" colspan="1">7 (77.8%)</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">17 (68.0%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">34 (66.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Peritoneal dialysis (%)</td><td align="center" rowspan="1" colspan="1">13 (14.3%)</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">2 (8.0%)</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">9 (17.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Post-transplant educational program (%)</td><td align="center" rowspan="1" colspan="1">37 (40.7%)</td><td align="center" rowspan="1" colspan="1">2 (22.2%)</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">3 (50.0%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">10 (40.0%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">22 (43.1%)</td></tr><tr><td colspan="9" align="left" rowspan="1">Treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Number of medications a day (IQR)</td><td align="center" rowspan="1" colspan="1">10 (8&#8211;13)</td><td align="center" rowspan="1" colspan="1">9 (8&#8211;11)</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">11.5 (8&#8211;17)</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">10 (7&#8211;11)</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">10 (8&#8211;14)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Pillbox use (%)</td><td align="center" rowspan="1" colspan="1">57 (62.0%)</td><td align="center" rowspan="1" colspan="1">8 (88.9%)</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">3 (50.0%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">17 (68.0%)</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">29 (56.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tacrolimus ER (%)</td><td align="center" rowspan="1" colspan="1">84 (92.3%)</td><td align="center" rowspan="1" colspan="1">6 (66.7%)</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">6 (100%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">25 (100%)</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">47 (92.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Corticosteroids (%)</td><td align="center" rowspan="1" colspan="1">62 (68.1%)</td><td align="center" rowspan="1" colspan="1">7 (77.8%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">14 (56.0%)</td><td align="center" rowspan="1" colspan="1">0.30</td><td align="center" rowspan="1" colspan="1">36 (70.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mycophenolate (%)</td><td align="center" rowspan="1" colspan="1">71 (78.0%)</td><td align="center" rowspan="1" colspan="1">5 (55.6%)</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">5 (83.3%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">22 (88.0%)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">39 (76.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Everolimus (%)</td><td align="center" rowspan="1" colspan="1">12 (13.2%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">3 (12.0%)</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">9 (17.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Azathioprine (%)</td><td align="center" rowspan="1" colspan="1">2 (2.2%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">0.20</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">1 (2.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Side effects (%)</td><td align="center" rowspan="1" colspan="1">19 (20.9%)</td><td align="center" rowspan="1" colspan="1">4 (44.4%)</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">3 (12.0%)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">11 (22.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunosuppressant possession ratio (IPR, median, IQR)</td><td align="center" rowspan="1" colspan="1">100% (98&#8211;100)</td><td align="center" rowspan="1" colspan="1">85% (76&#8211;89)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">93% (92&#8211;94)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">98% (97&#8211;99)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100% (100&#8211;100)</td></tr><tr><td colspan="9" align="left" rowspan="1">Tacrolimus exposure</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tacrolimus trough levels coefficient of variation (CV<sub>TAC,</sub> median, IQR)</td><td align="center" rowspan="1" colspan="1">26.2 (20.8&#8211;30.7)</td><td align="center" rowspan="1" colspan="1">32.0 (24.7&#8211;36.6)</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">27.3 (23.2&#8211;28.7)</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">22.0 (19.0&#8211;28.4)</td><td align="center" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="center" rowspan="1" colspan="1">26.3 (21.5&#8211;30.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Number of patients with a CV<sub>TAC</sub> &gt; 30% (%)</td><td align="center" rowspan="1" colspan="1">26 (28.6%)</td><td align="center" rowspan="1" colspan="1">6 (66.7%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="center" rowspan="1" colspan="1">1 (16.7%)</td><td align="center" rowspan="1" colspan="1">0.67</td><td align="center" rowspan="1" colspan="1">4 (16%)</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">15 (29.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Number of patients who claimed having forgotten to take their medicine since transplantation at least once (%)</td><td align="center" rowspan="1" colspan="1">14 (15.4%)</td><td align="center" rowspan="1" colspan="1">4 (44.4%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">3 (13.6%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="center" rowspan="1" colspan="1">7 (15.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least one missed outpatient visit since transplantation (%)</td><td align="center" rowspan="1" colspan="1">25 (27.5%)</td><td align="center" rowspan="1" colspan="1">6 (66.7%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="center" rowspan="1" colspan="1">2 (33.3%)</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">4 (16%)</td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">13 (25.5%)</td></tr></tbody></table><table-wrap-foot><fn><p>ER, extended-release; IQR, interquartile range; IPR, immunosuppressant possession ratio; SR, standard-release. Quantitative variables are reported as: median (IQR).</p></fn><fn><p>Results in bold are the number of patients, column labels and significant p-values (&lt;0,05).</p></fn></table-wrap-foot></table-wrap><p>At inclusion, we were able to calculate the IPR since transplantation in all these patients, and the mean time needed to calculate was approximatively 45&#160;min per patient (<xref rid="F2" ref-type="fig">Figure 2</xref>). IPR ranged from 49% to 100% with a median (IQR) of 100% (97&#8211;100).</p></sec><sec id="s3-2"><title>Immunosuppressant Possession Ratio Since Transplantation Is Associated With Other Markers of Non-Adherence</title><p>In the first cohort, patients were divided into three groups according to their IPR (&lt;90%, 90%&#8211;94%, 95%&#8211;99%) and compared to the patients with an IPR = 100%, in order to determine an optimal non-adherence threshold. Nine patients had an IPR&lt;90% (9.9%) 6 patients an IPR of 90%&#8211;94% (6.6%), 25 patients an IPR of 95%&#8211;99% (27.5%), and 51 patients an IPR = 100% (56.0%) (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>Patients with an IPR &lt; 90% had more frequently a CV<sub>TAC</sub> &gt; 30% (66.7% vs<italic toggle="yes">.</italic> 29.4%, <italic toggle="yes">p</italic> = 0.05), and claimed to have forgotten to take their medication more frequently (44.4% vs<italic toggle="yes">.</italic> 15.9% <italic toggle="yes">p</italic> = 0.05) than patients with an IPR = 100%. Patients with IPRs&lt;90% were also more likely to miss at least one outpatient visit (66.7% vs<italic toggle="yes">.</italic> 25.5%, <italic toggle="yes">p</italic> = 0.02) than patients with IPRs = 100% (<xref rid="T1" ref-type="table">Table 1</xref>). Patients with an IPR of 95%&#8211;99% had a lower CV<sub>TAC</sub> (22.0% vs 26.3%, <italic toggle="yes">p</italic> = 0.05) than patients with IPRs = 100% (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>In summary, patients with an IPRs &lt; 90% exhibited more frequently other markers of non-adherence.</p></sec><sec id="s3-3"><title>Calculation of the Immunosuppressant Possession Ratio Over a Standardized Period</title><p>We then tried to determine the optimal duration for calculating the IPR in order to standardize the measurement of this variable. We observed a poor correlation between the IPR calculated over the previous 3&#160;months period and the IPR calculated since transplantation (<italic toggle="yes">&#961;</italic> = 0.49). We observed a very good correlation between the IPR calculated over the previous 12&#160;months and the previous 6&#160;months period and the IPR calculated since transplantation (<italic toggle="yes">&#961;</italic> = 0.93, and <italic toggle="yes">&#961;</italic> = 0.8, respectively) (<xref rid="F3" ref-type="fig">Figure 3</xref>). In summary, the IPR seemed to be calculated reliably over a period of 6 or 12&#160;months. However, the 6&#160;months IPR was used for the rest of the study because it is faster to calculate and more representative of current adherence than the 12&#160;months IPR.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Correlations between immunosuppressant possession ratios since transplantation and three standardized periods The immunosuppressants possession ratio (IPR) was calculated since transplantation for all 91 patients, over the previous 12&#160;months in 52 patients, over the previous 6&#160;months in 91 patients, and over the previous 3&#160;months in 91 patients <bold>(A)</bold>. Spearman correlations were performed between the IPRs calculated since transplantation and the IPRs calculated over the previous 12&#160;months <bold>(B)</bold>, 6&#160;months <bold>(C)</bold> and 3&#160;months <bold>(D)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ti-36-11962-g003.jpg"/></fig></sec><sec id="s3-4"><title>Six-Month Immunosuppressant Possession Ratio at the Time of Clinical Histological Antibody-Mediated Rejection Diagnosis</title><p>We next tested the association of 6&#160;months IPR with the occurrence of clinical hABMR in the retrospective cohort 2. Among 222 for-cause biopsies for the period considered, 26 patients with clinical hABMR were compared to 26 patients with IFTA (<xref rid="F1" ref-type="fig">Figure 1B</xref>). The patients&#8217; characteristics at the time of the for-cause biopsy are depicted in <xref rid="T2" ref-type="table">Table 2</xref>. No patients had preformed anti-HLA DSA. <italic toggle="yes">De novo</italic> anti-HLA DSA were found in 15/26 patients (57.7%) with clinical hABMR and in 4/26 patients (15.4%) with IFTA (<italic toggle="yes">p</italic> = 0.03).</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Patients&#8217; characteristics in retrospective cohort 2.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All (<italic toggle="yes">n</italic> = 52)</th><th align="center" rowspan="1" colspan="1">Histological antibody-mediated rejection (<italic toggle="yes">n</italic> = 26)</th><th align="center" rowspan="1" colspan="1">Interstitial fibrosis and tubular atrophy (<italic toggle="yes">n</italic> = 26)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" rowspan="1">Baseline characteristics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Age (years, median, IQR)</td><td align="center" rowspan="1" colspan="1">49 (42&#8211;62)</td><td align="center" rowspan="1" colspan="1">50 (41&#8211;63)</td><td align="center" rowspan="1" colspan="1">49 (45&#8211;59)</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Female (%)</td><td align="center" rowspan="1" colspan="1">24 (46.2%)</td><td align="center" rowspan="1" colspan="1">12 (46.2%)</td><td align="center" rowspan="1" colspan="1">12 (46.2%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Time since transplantation (months, IQR)</td><td align="center" rowspan="1" colspan="1">81 (41.3&#8211;173.3)</td><td align="center" rowspan="1" colspan="1">88.5 (41.3&#8211;155.3)</td><td align="center" rowspan="1" colspan="1">72.5 (40.8&#8211;192.3)</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td colspan="5" align="left" rowspan="1">Treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tacrolimus ER (%)</td><td align="center" rowspan="1" colspan="1">29 (55.8%)</td><td align="center" rowspan="1" colspan="1">14 (53.9%)</td><td align="center" rowspan="1" colspan="1">15 (57.7%)</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tacrolimus SR (%)</td><td align="center" rowspan="1" colspan="1">8 (15.3%)</td><td align="center" rowspan="1" colspan="1">5 (19.2%)</td><td align="center" rowspan="1" colspan="1">3 (11.5%)</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cyclosporine (%)</td><td align="center" rowspan="1" colspan="1">13 (25.0%)</td><td align="center" rowspan="1" colspan="1">6 (23.1%)</td><td align="center" rowspan="1" colspan="1">7 (26.9%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Corticosteroids (%)</td><td align="center" rowspan="1" colspan="1">35 (67.3%)</td><td align="center" rowspan="1" colspan="1">19 (73.0%)</td><td align="center" rowspan="1" colspan="1">16 (61.5%)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Mycophenolate (%)</td><td align="center" rowspan="1" colspan="1">34 (65.4%)</td><td align="center" rowspan="1" colspan="1">17 (65.4%)</td><td align="center" rowspan="1" colspan="1">17 (65.4%)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Everolimus (%)</td><td align="center" rowspan="1" colspan="1">4 (7.7%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (15.4%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Azathioprin (%)</td><td align="center" rowspan="1" colspan="1">1 (1.9%)</td><td align="center" rowspan="1" colspan="1">1 (3.8%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Sirolimus (%)</td><td align="center" rowspan="1" colspan="1">1 (1.9%)</td><td align="center" rowspan="1" colspan="1">1 (3.8%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td colspan="5" align="left" rowspan="1">Renal injury</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Microvascular inflammation (g + ptc, median, IQR)</td><td align="center" rowspan="1" colspan="1">1 (0&#8211;3)</td><td align="center" rowspan="1" colspan="1">3 (2&#8211;3)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;0)</td><td align="center" rowspan="1" colspan="1">
<bold>&lt; 0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;C4d graft deposition (%)</td><td align="center" rowspan="1" colspan="1">12 (23.1%)</td><td align="center" rowspan="1" colspan="1">12 (46.2%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">
<bold>&lt; 0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Transplant glomerulopathy (cg, median, IQR)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;2)</td><td align="center" rowspan="1" colspan="1">1 (0&#8211;2)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;0)</td><td align="center" rowspan="1" colspan="1">
<bold>&lt; 0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Interstitial inflammation and tubulitis (i + t, median, IQR)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;1)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;1)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;1)</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Interstitial fibrosis and tubular atrophy (ct + ci, median, IQR)</td><td align="center" rowspan="1" colspan="1">4 (2&#8211;4)</td><td align="center" rowspan="1" colspan="1">4 (2&#8211;6)</td><td align="center" rowspan="1" colspan="1">3.5 (2&#8211;4)</td><td align="center" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Arteriosclerosis (cv, median, IQR)</td><td align="center" rowspan="1" colspan="1">1 (0&#8211;2)</td><td align="center" rowspan="1" colspan="1">1 (0&#8211;2)</td><td align="center" rowspan="1" colspan="1">2 (1&#8211;3)</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td colspan="5" align="left" rowspan="1">
<italic toggle="yes">De novo</italic> anti-HLA donor specific antibodies (DSA)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;DSA (%)</td><td align="center" rowspan="1" colspan="1">19 (38%)</td><td align="center" rowspan="1" colspan="1">15 (57.7%)</td><td align="center" rowspan="1" colspan="1">4 (15.4%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Only class I DSA (%)</td><td align="center" rowspan="1" colspan="1">1 (1.9%)</td><td align="center" rowspan="1" colspan="1">1 (3.8%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Only class II DSA (%)</td><td align="center" rowspan="1" colspan="1">10 (19.2%)</td><td align="center" rowspan="1" colspan="1">7 (26.9%)</td><td align="center" rowspan="1" colspan="1">3 (11.5%)</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Class I + II DSA (%)</td><td align="center" rowspan="1" colspan="1">8 (15.4%)</td><td align="center" rowspan="1" colspan="1">7 (26.9%)</td><td align="center" rowspan="1" colspan="1">1 (3.8%)</td><td align="center" rowspan="1" colspan="1">
<bold>0.05</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Sum of DSA MFI (arbitrary unit, median, IQR)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;4,767)</td><td align="center" rowspan="1" colspan="1">3,542 (0&#8211;18,985)</td><td align="center" rowspan="1" colspan="1">0 (0&#8211;0)</td><td align="center" rowspan="1" colspan="1">
<bold>&lt; 0.001</bold>
</td></tr><tr><td colspan="5" align="left" rowspan="1">Treatment exposure</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 32</bold>
<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 14</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 18</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Last tacrolimus trough level (ng/mL, IQR)</td><td align="center" rowspan="1" colspan="1">6.3 (5.5&#8211;7.9)</td><td align="center" rowspan="1" colspan="1">6.6 (6.0&#8211;8.5)</td><td align="center" rowspan="1" colspan="1">5.9 (5.1&#8211;7.8)</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 31</bold>
<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 13</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 18</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Tacrolimus trough level coefficient of variation (CV<sub>TAC,</sub> median, IQR)</td><td align="center" rowspan="1" colspan="1">24.4 (14.2&#8211;34.7)</td><td align="center" rowspan="1" colspan="1">17.5 (12.8&#8211;37.8)</td><td align="center" rowspan="1" colspan="1">30.0 (16.6&#8211;35.2)</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 13</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 6</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic> = 7</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Last cyclosporine through level (ng/mL, IQR)</td><td align="center" rowspan="1" colspan="1">121 (92&#8211;152)</td><td align="center" rowspan="1" colspan="1">103 (65&#8211;147)</td><td align="center" rowspan="1" colspan="1">143 (104&#8211;178)</td><td align="center" rowspan="1" colspan="1">0.23</td></tr></tbody></table><table-wrap-foot><fn><p>DSA, donor-specific antibodies; ER, extended-release- IQR, interquartile range-SR, standard-release; MFI, mean fluorescence intensity. Quantitative variables are reported as: median (IQR).</p></fn><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>15 patients were not treated with tacrolimus and 5 patients had no tacrolimus trough level available on the last year.</p></fn><fn id="Tfn2"><label>
<sup>b</sup>
</label><p>A minimum of three available plasma concentration values was required to calculate the tacrolimus coefficient of variation: incomplete data for one patient.</p></fn><fn><p>Results in bold are the number of patients, column labels and significant p-values (&lt;0,05).</p></fn></table-wrap-foot></table-wrap><p>The 6&#160;months IPR was calculated from the day of the biopsy for the 52 patients. Patients with clinical hABMR had a lower 6&#160;months IPR than patients with IFTA (76% vs<italic toggle="yes">.</italic> 99%, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). Univariable analysis identified only <italic toggle="yes">de novo</italic> DSA and 6&#160;months IPR as risk factors for hABMR. In a first multivariable analysis (model 1), these two variables were independently associated with hABMR (odds ratio, 4.66; 95% CI, 1.19&#8211;20.94; <italic toggle="yes">p</italic> = 0.03, and odds ratio, 0.73 per 10% increase; 95% CI, 0.51&#8211;0.98; <italic toggle="yes">p</italic> = 0.05, respectively) (<xref rid="T3" ref-type="table">Table 3</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Immunosuppressant possession ratio and clinical suspicion of non-adherence in patients with clinical histological antibody-mediated rejection (hABMR) or interstitial fibrosis with tubular atrophy (IFTA). Description of the immunosuppressant possession ratios calculated over the previous 6&#160;months in patients with a clinical hABMR and IFTA <bold>(A)</bold>. Contingency table of non-adherence identified by immunosuppressant possession ratio &lt;90% over the previous 6&#160;months and clinical suspicion <bold>(B)</bold>. Non-adherence identified by clinical suspicion and immunosuppressant possession ratio &lt;90% over the previous 6&#160;months in patients with a clinical hABMR and IFTA <bold>(C)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ti-36-11962-g004.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Factors associated with histological antibody-mediated rejection.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="2" align="left" colspan="1">Variable</th><th colspan="2" align="center" rowspan="1">Univariable analysis</th><th colspan="2" align="center" rowspan="1">Multivariable analysis model 1</th><th colspan="2" align="center" rowspan="1">Multivariable analysis model 2</th></tr><tr><th align="center" rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th><th align="center" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th><th align="center" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">0.99 (0.96&#8211;1.04)</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male sex (male <italic toggle="yes">versus</italic> female)</td><td align="center" rowspan="1" colspan="1">1.00 (0.33&#8211;3.00)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Time since transplantation (months)</td><td align="center" rowspan="1" colspan="1">1.00 (0.99&#8211;1.01)</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tacrolimus versus cyclosporine</td><td align="center" rowspan="1" colspan="1">1.23 (0.35&#8211;5.51)</td><td align="center" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mycophenolate versus other</td><td align="center" rowspan="1" colspan="1">1.00 (0.29&#8211;3.46)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids</td><td align="center" rowspan="1" colspan="1">1.00 (0.58&#8211;1.73)</td><td align="center" rowspan="1" colspan="1">&gt;0.99</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tacrolimus trough level coefficient of variation &gt;30%</td><td align="center" rowspan="1" colspan="1">0.58 (0.17&#8211;1.93)</td><td align="center" rowspan="1" colspan="1">0.38</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">De novo</italic> DSA<sup>1, 2</sup>
</td><td align="center" rowspan="1" colspan="1">7.50 (2.15&#8211;31.53)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">4.66 (1.19&#8211;20.94)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">4.73 (1.17&#8211;21.88)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">6-month IPR (10% increase)<sup>1</sup>
</td><td align="center" rowspan="1" colspan="1">0.67 (0.47&#8211;0.87)</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.73 (0.51&#8211;0.98)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-adherence based on 6-month IPR &lt;90%<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">9.05 (2.72&#8211;34.46)</td><td align="center" rowspan="1" colspan="1">0.0006</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.34 (1.73&#8211;25.59)</td><td align="center" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-adherence based on clinician suspicion<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">11.11 (1.81&#8211;215.6)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>IPR, immunosuppressant Possession ratio. Covariates with <italic toggle="yes">p</italic>-values &lt; 0.2 on univariable analyses were included into a multiple logistic regression then iteratively removed retaining only those with a <italic toggle="yes">p</italic>-value &#8804; 0.05. Variables with the index <sup>(1)</sup> were used in the model 1. Variables with the index <sup>(2)</sup> were used in the model 2.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-5"><title>Diagnosis of Non-Adherence Based on 6&#160;Month Immunosuppressant Possession Ratio Below 90%</title><p>ROC curve analysis showed that the IPR was a good predictor of hABMR (AUC = 0.79). The optimal predictive threshold of IPR for clinical hABMR occurrence was 92% with a 77% sensitivity and 77% specificity (<xref rid="s9" ref-type="sec">Supplementary Figure S1</xref>). This threshold value was very close to 90% found in cohort 1. Therefore, we chose to compare the diagnosis of non-adherence based on the 6&#160;months IPR &lt; 90% with our standard method based on clinical suspicion. Across the whole cohort, non-adherence was more often diagnosed with the definition based on a 6&#160;months IPR &lt; 90% (25/52 patients) than with the clinical suspicion (9/52 patients) (48.1% vs<italic toggle="yes">.</italic> 17.3%, <italic toggle="yes">p</italic> &lt; 0.001). The diagnosis of non-adherence was achieved by the two methods in 9 KTR (17.3%) and by the IPR &lt; 90% alone in 16 KTR (30.8%). All the patients with a clinical suspicion of non-adherence had an IPR &lt; 90% (<xref rid="F4" ref-type="fig">Figure 4B</xref>).</p><p>The proportion of non-adherent KTRs, based on a 6&#160;months IPR &lt; 90% was much higher in the clinical hABMR group (19/26 patients) than in the IFTA group (6/26 patients) (73.1% vs<italic toggle="yes">.</italic> 23.1%, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="F4" ref-type="fig">Figure 4C</xref>). In KTRs with clinical hABMR, the percentage of non-adherent KTRs was higher with the definition based on an IPR &lt; 90% (19/26 patients) than with the clinical suspicion (8/26 patients) (73.1% vs<italic toggle="yes">.</italic> 30.8%, <italic toggle="yes">p</italic> = 0.02) (<xref rid="F4" ref-type="fig">Figure 4C</xref>). In KTRs with IFTA, the percentage of non-adherence was also higher with the definition based on an IPR &lt; 90%, but the difference was not significant (23.1% vs<italic toggle="yes">.</italic> 3.8%, <italic toggle="yes">p</italic> = 0.07). Similar results were observed with the 12&#160;months IPR (<xref rid="s9" ref-type="sec">Supplementary Figure S2</xref>).</p><p>Univariable analysis also identified 6&#160;months IPR &lt; 90% and non-adherence based on clinical suspicion as risk factors for hABMR (<xref rid="T3" ref-type="table">Table 3</xref>). In a second multivariable analysis including these two variables and <italic toggle="yes">de novo</italic> DSA (model 2), only <italic toggle="yes">de novo</italic> DSA and 6&#160;months IPR &lt; 90% were independently associated with hABMR (odds ratio, 4.73; 95% CI, 1.17&#8211;21.88; <italic toggle="yes">p</italic> = 0.03; and odds ratio, 6.34; 95% CI, 1.73&#8211;25.59; <italic toggle="yes">p</italic> = 0.007, respectively).</p><p>We finally used the NRI to compare the clinical utility of the 6&#160;months IPR&lt;90% with the clinical suspicion, for the prediction of hABMR. Compared with clinical suspicion, a 6&#160;months IPR &lt; 90% adequately reclassified 42% of patients within the hABMR group, but misclassified 19% of patients of the IFTA group, resulting in a non-significant overall NRI of 0.23 (95% CI &#8722;0.07&#8211;0.53; <italic toggle="yes">p</italic> = 0.13).</p></sec><sec id="s3-6"><title>Immunosuppressant Possession Ratio in Clinical Histological Antibody-Mediated Rejections Related to Anti-HLA DSA</title><p>Regardless of histological lesions, <italic toggle="yes">de novo</italic> anti-HLA DSA-positive patients, had a lower 6&#160;months IPR than anti-HLA DSA-negative patients (71% vs<italic toggle="yes">.</italic> 98%, <italic toggle="yes">p</italic> = 0.004) (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Patients with a <italic toggle="yes">de novo</italic> anti-HLA DSA-positive clinical hABMR had a lower 6&#160;months IPR than patients with anti-HLA DSA-negative clinical hABMR (61% vs<italic toggle="yes">.</italic> 89%, <italic toggle="yes">p</italic> = 0.03). Patients with anti-HLA DSA-negative clinical hABMR also had a lower 6&#160;months IPR than patients with IFTA (89% vs<italic toggle="yes">.</italic> 99%, p 0.02) (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Moreover, the proportion of KTRs with a 6&#160;months IPR &lt; 90% was much higher in the anti-HLA DSA-positive clinical hABMR group than in the anti-HLA DSA-negative clinical hABMR and IFTA groups (86.7%, 54.5% and 23.1%, respectively, <italic toggle="yes">p</italic> &lt; 0.001) (<xref rid="F5" ref-type="fig">Figure 5C</xref>). Similar results were observed with the 12&#160;months IPR (<xref rid="s9" ref-type="sec">Supplementary Figure S3</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Immunosuppressant possession ratio in patients with or without <italic toggle="yes">de novo</italic> anti-HLA donor-specific antibody (DSA). Description of the immunosuppressant possession ratios calculated over the previous 6&#160;months in patients with or without anti-HLA DSA <bold>(A)</bold>. Description of the immunosuppressant possession ratios calculated over the previous 6&#160;months <bold>(B)</bold> in anti-HLA DSA-positive hABMR, anti-HLA DSA-negative hABMR and IFTA groups. Immunosuppressant possession ratio &lt;90% over the previous 6&#160;months <bold>(C)</bold> in anti-HLA DSA-positive hABMR, anti-HLA DSA-negative hABMR and IFTA groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ti-36-11962-g005.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This study showed that the prospective calculation of a real-time IPR after transplantation is feasible thanks to a close collaboration between transplant clinical pharmacists and community pharmacists. This IPR was correlated with a high intra-patient variability of tacrolimus trough level and outpatient visit non-adherence. Low IPRs were found at the time of clinical hABMR, especially in patients with <italic toggle="yes">de novo</italic> DSA. This tool was better associated with hABMR than clinical suspicion.</p><p>Nowadays, pharmacy management software packages are exhaustive and contain all prescription refill data. These data can be obtained very easily thanks to a close collaboration between the transplant clinical pharmacist and the patient&#8217;s pharmacist. By combining them with a reliable collection of each dose change and hospitalization days in the patient&#8217;s medical record, it is simple to calculate a very precise IPR for each patient.</p><p>We chose to use mycophenolate as a priority for IPR calculation because variations in dosage are infrequent and there are only two commercially available dosages. This method works for brand-name and generic drugs, regardless of the formulation. For those who did not receive mycophenolate, we chose another immunosuppressant with which the calculation of the IPR was simple. We avoided using calcineurin inhibitors because patients must regularly use several different pills of tacrolimus and the dose can vary very frequently. These variations make IPR analysis for calcineurin inhibitors more difficult.</p><p>The IPR calculated over a 3&#160;months period was poorly correlated with the IPR calculated for a period of between 8 and 16&#160;months. Some drug packages allow the patient to collect their treatment for 2 or 3&#160;months in a single dispensing. Some patients therefore could have a high IPR over a 3&#160;months period, based on a single dispensing of medication. Choosing to calculate the IPR over a 6&#160;months period seems to be a good compromise because it allows to obtain a reliable, fast and representative calculation of the current adherence.</p><p>Patients with IPRs &lt; 90% had higher tacrolimus trough level coefficients of variation compared to patients with IPRs = 100%. This could be explained by a correlation between the mycophenolate possession ratio and the tacrolimus possession ratio. Nevertheless, the latter was not calculated due to its complexity. Patients with an IPR &lt; 90% also claimed to take their medicine less frequently. We also showed that patients with IPRs &lt; 90% were more likely to have had at least one missed visit (66.7% vs. 23.2%, <italic toggle="yes">p</italic> = 0.01). These results are in line with the study of Taber et al. which showed that non-adherence to outpatient visits was strongly correlated with non-adherence to treatment, and both were predictive of adverse clinical consequences [<xref rid="B16" ref-type="bibr">16</xref>]. Based on these results, we defined the non-adherent patients as those having a threshold of IPR &lt; 90%. Only 10% of the patients in Cohort 1 had an IPR &lt; 90%. This can be explained by the fact that our patients were adults who had recently been transplanted and because the French health system covers the full cost of immunosuppressants.</p><p>It has been reported in previous retrospective studies that non-adherence to immunosuppressants was associated with <italic toggle="yes">de novo</italic> DSA and ABMR [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. In these studies, non-adherence to immunosuppressants was suspected by transplant physicians. Our study shows that the 6&#160;months IPR &lt; 90% was the only non-adherence measurement tool independently associated with hABMR. It allowed to identify 42% of hABMR patients who had been misclassified by clinical suspicion, confirming the low sensitivity of this latter method [<xref rid="B18" ref-type="bibr">18</xref>]. It is also worth noting that measurement of non-adherence with the tacrolimus trough level coefficients of variation was not possible for around half of the patients because they were non-adherent to the recommended biological follow-up. Moreover, the tacrolimus trough level coefficients of variation was not associated with hABMR.</p><p>The overall NRI showed only a trend toward a better prediction of hABMR by the IPR &lt; 90% when compared to clinical suspicion. The better identification of hABMR in patients with an IPR &lt; 90% comes at a price of 23.1% of false positive, namely, patients with an IPR &lt; 90% in the IFTA group. A low IPR necessarily implies poor adherence to immunosuppressants, because a patient cannot take treatments he has not collected. Therefore, these 23.1% of false positive patients could be at risk of developing rejection in the future. They may also have acquired operational tolerance, but these two hypotheses deserve to be explored.</p><p>The IPR was the lowest in positive anti-HLA DSA-ABMR, but negative anti-HLA DSA-ABMR also had a lower IPR than the control group. Negative anti-HLA DSA-ABMR is an entity caused by non HLA-DSA or missing-self induced microvascular rejection [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>]. Our data suggest that non-adherence could also be associated with these recently identified rejections.</p><p>One of the limitations of the IPR measurement is that it may be biased if the patient visits different pharmacies without informing medical staff. This phenomenon is rare in France because pharmacies order these expensive treatments only for their usual patients. In addition, patients were asked to report any pharmacy changes. Additionally, patients with IPR = 100% were considered as adherent, but it does not determine whether patients were taking the right dose, even if they had collected their medication from the pharmacy. Another limitation of our study was the small sample size of the two cohorts. However, this did not prevent us from achieving the objectives of the study.</p><p>In summary, IPR calculation by transplant clinical pharmacists can be used to diagnose immunosuppressant non-adherence in patients with hABMR. This tool could allow continuous monitoring of adherence and thus take into account the dynamic and individual nature of non-adherence over time. In addition, it could generate a red flag for transplant physicians and pharmacists about patients who are non-adherent to their outpatient visits. Prospective studies are urgently needed to determine its ability to predict all kinds of rejection and graft losses. At the same time, the optimal threshold of IPR associated with the onset of <italic toggle="yes">de novo</italic> DSA and ABMR will have to be determined. An automatic calculation could be envisioned by aggregating the prescription refills which are stored in the national health data system and patients&#8217; medical records in order to save pharmacists time.</p></sec></body><back><ack><p>We sincerely thank pharmacists Anne Colombe and Frederique Pribat for providing materials prior to the study, our student Marin Laurent for his help in collecting the data, the Department of Clinical Pharmacology of our hospital (Pr. Molimard, Dr. Titier) for providing the tacrolimus concentration data and the renal transplantation team (secretaries, nurses, doctors) for their help in organizing the consultations.</p></ack><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p></sec><sec id="s6"><title>Ethics Statement</title><p>The studies involving humans were approved by French CNIL final agreement, decision 2009-413, n&#176; 1357154, 2 July 2009. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec id="s7"><title>Author Contributions</title><p>JC: designed study, performed study, collected and analyzed data, wrote the paper; FX and KM: designed study, revised the paper; JeV, BT, BC, and JoV: collected and analyzed data, revised the paper; PM and SD: designed study, analyzed data, revised the paper; LC: designed study, collected and analyzed data, wrote the paper. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="s9"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11962/full#supplementary-material" ext-link-type="uri">https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11962/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image3.TIF" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image2.TIF" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image1.TIF" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><sec id="s10"><title>Abbreviations</title><p>ABMR, antibody-mediated rejection; CV<sub>TAC</sub>, tacrolimus trough levels coefficient of variation; CV<sub>CsA</sub>, cyclosporine trough levels coefficient of variation; DSA, donor-specific antibodies; g, glomerulitis; hABMR, histological antibody-mediated rejection; IFTA, interstitial fibrosis and tubular atrophy; IPR, immunosuppressant possession ratio; KTR, kidney transplant recipients; ptc, peritubular capillaritis; SAFB, single-antigen flow beads assays.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>RN</given-names></name><name name-style="western"><surname>Becker</surname><given-names>Y</given-names></name><name name-style="western"><surname>De Geest</surname><given-names>S</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ettenger</surname><given-names>R</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R</given-names></name><etal/></person-group><article-title>Nonadherence Consensus Conference Summary Report: Nonadherence Consensus Conference Summary Report</article-title>. <source>Am J Transpl</source> (<year>2008</year>) <volume>9</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2008.02495.x</pub-id><pub-id pub-id-type="pmid">19133930</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dew</surname><given-names>MA</given-names></name><name name-style="western"><surname>DiMartini</surname><given-names>AF</given-names></name><name name-style="western"><surname>De Vito Dabbs</surname><given-names>A</given-names></name><name name-style="western"><surname>Myaskovsky</surname><given-names>L</given-names></name><name name-style="western"><surname>Steel</surname><given-names>J</given-names></name><name name-style="western"><surname>Unruh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rates and Risk Factors for Nonadherence to the Medical Regimen After Adult Solid Organ Transplantation</article-title>. <source>Transplantation</source> (<year>2007</year>) <volume>83</volume>(<issue>7</issue>):<fpage>858</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/01.tp.0000258599.65257.a6</pub-id><pub-id pub-id-type="pmid">17460556</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>JA</given-names></name><name name-style="western"><surname>Roderick</surname><given-names>P</given-names></name><name name-style="western"><surname>Mullee</surname><given-names>M</given-names></name><name name-style="western"><surname>Mason</surname><given-names>JC</given-names></name><name name-style="western"><surname>Peveler</surname><given-names>RC</given-names></name></person-group>. <article-title>Frequency and Impact of Nonadherence to Immunosuppressants After Renal Transplantation: A Systematic Review</article-title>. <source>Transplantation</source> (<year>2004</year>) <volume>77</volume>(<issue>5</issue>):<fpage>769</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1097/01.tp.0000110408.83054.88</pub-id><pub-id pub-id-type="pmid">15021846</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>B</given-names></name><name name-style="western"><surname>Morin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Albano</surname><given-names>L</given-names></name><name name-style="western"><surname>Godin</surname><given-names>M</given-names></name><name name-style="western"><surname>Barrou</surname><given-names>B</given-names></name><etal/></person-group><article-title>Factors Predictive of Medication Nonadherence After Renal Transplantation: A French Observational Study</article-title>. <source>Transplantation</source> (<year>2013</year>) <volume>95</volume>(<issue>2</issue>):<fpage>326</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e318271d7c1</pub-id><pub-id pub-id-type="pmid">23149477</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Geest</surname><given-names>S</given-names></name><name name-style="western"><surname>Burkhalter</surname><given-names>H</given-names></name><name name-style="western"><surname>Bogert</surname><given-names>L</given-names></name><name name-style="western"><surname>Berben</surname><given-names>L</given-names></name><name name-style="western"><surname>Glass</surname><given-names>TR</given-names></name><name name-style="western"><surname>Denhaerynck</surname><given-names>K</given-names></name><etal/></person-group><article-title>Describing the Evolution of Medication Nonadherence From Pretransplant Until 3 Years Post-Transplant and Determining Pretransplant Medication Nonadherence as Risk Factor for Post-Transplant Nonadherence to Immunosuppressives: The Swiss Transplant Cohort Study</article-title>. <source>Transpl Int</source> (<year>2014</year>) <volume>27</volume>(<issue>7</issue>):<fpage>657</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1111/tri.12312</pub-id><pub-id pub-id-type="pmid">24628915</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>C</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>IW</given-names></name><name name-style="western"><surname>Blydt-Hansen</surname><given-names>TD</given-names></name><name name-style="western"><surname>Pochinco</surname><given-names>D</given-names></name><name name-style="western"><surname>Birk</surname><given-names>PE</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><etal/></person-group><article-title>Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With <italic toggle="yes">De Novo</italic> Donor-Specific Antibody: Post-<italic toggle="yes">Dn</italic> DSA Clinical Histologic Progression</article-title>. <source>Am J Transpl</source> (<year>2015</year>) <volume>15</volume>(<issue>11</issue>):<fpage>2921</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.13347</pub-id><pub-id pub-id-type="pmid">26096305</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellar&#233;s</surname><given-names>J</given-names></name><name name-style="western"><surname>de Freitas</surname><given-names>DG</given-names></name><name name-style="western"><surname>Mengel</surname><given-names>M</given-names></name><name name-style="western"><surname>Reeve</surname><given-names>J</given-names></name><name name-style="western"><surname>Einecke</surname><given-names>G</given-names></name><name name-style="western"><surname>Sis</surname><given-names>B</given-names></name><etal/></person-group><article-title>Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence</article-title>. <source>Am J Transpl</source> (<year>2012</year>) <volume>12</volume>(<issue>2</issue>):<fpage>388</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03840.x</pub-id><pub-id pub-id-type="pmid">22081892</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malheiro</surname><given-names>J</given-names></name><name name-style="western"><surname>Santos</surname><given-names>S</given-names></name><name name-style="western"><surname>Tafulo</surname><given-names>S</given-names></name><name name-style="western"><surname>Dias</surname><given-names>L</given-names></name><name name-style="western"><surname>Martins</surname><given-names>LS</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>I</given-names></name><etal/></person-group><article-title>Correlations Between Donor-Specific Antibodies and Non-adherence With Chronic Active Antibody-Mediated Rejection Phenotypes and Their Impact on Kidney Graft Survival</article-title>. <source>Hum Immunol</source> (<year>2018</year>) <volume>79</volume>(<issue>6</issue>):<fpage>413</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2018.03.004</pub-id><pub-id pub-id-type="pmid">29577962</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G</given-names></name><name name-style="western"><surname>Abu Jawdeh</surname><given-names>BG</given-names></name><name name-style="western"><surname>Racusen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Bhasin</surname><given-names>B</given-names></name><name name-style="western"><surname>Arend</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Trollinger</surname><given-names>B</given-names></name><etal/></person-group><article-title>Late Antibody-Mediated Rejection in Renal Allografts: Outcome After Conventional and Novel Therapies</article-title>. <source>Transplantation</source> (<year>2014</year>) <volume>97</volume>(<issue>12</issue>):<fpage>1240</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/01.TP.0000442503.85766.91</pub-id><pub-id pub-id-type="pmid">24937198</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>C</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>IW</given-names></name><name name-style="western"><surname>Blydt-Hansen</surname><given-names>TD</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><name name-style="western"><surname>Storsley</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Evolution and Clinical Pathologic Correlations of De Novo Donor-specific HLA Antibody Post Kidney Transplant: Clinical Pathologic Correlations of De Novo DSA</article-title>. <source>Am J Transpl</source> (<year>2012</year>) <volume>12</volume>(<issue>5</issue>):<fpage>1157</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04013.x</pub-id><pub-id pub-id-type="pmid">22429309</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takemoto</surname><given-names>SK</given-names></name><name name-style="western"><surname>Pinsky</surname><given-names>BW</given-names></name><name name-style="western"><surname>Schnitzler</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lentine</surname><given-names>KL</given-names></name><name name-style="western"><surname>Willoughby</surname><given-names>LM</given-names></name><name name-style="western"><surname>Burroughs</surname><given-names>TE</given-names></name><etal/></person-group><article-title>A Retrospective Analysis of Immunosuppression Compliance, Dose Reduction and Discontinuation in Kidney Transplant Recipients</article-title>. <source>Am J Transpl d&#233;c</source> (<year>2007</year>) <volume>7</volume>(<issue>12</issue>):<fpage>2704</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2007.01966.x</pub-id><pub-id pub-id-type="pmid">17868065</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinsky</surname><given-names>BW</given-names></name><name name-style="western"><surname>Takemoto</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lentine</surname><given-names>KL</given-names></name><name name-style="western"><surname>Burroughs</surname><given-names>TE</given-names></name><name name-style="western"><surname>Schnitzler</surname><given-names>MA</given-names></name><name name-style="western"><surname>Salvalaggio</surname><given-names>PR</given-names></name></person-group>. <article-title>Transplant Outcomes and Economic Costs Associated With Patient Noncompliance to Immunosuppression</article-title>. <source>Am J Transpl</source> (<year>2009</year>) <volume>9</volume>(<issue>11</issue>):<fpage>2597</fpage>&#8211;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02798.x</pub-id><pub-id pub-id-type="pmid">19843035</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaynor</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ciancio</surname><given-names>G</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>G</given-names></name><name name-style="western"><surname>Sageshima</surname><given-names>J</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>L</given-names></name><name name-style="western"><surname>Roth</surname><given-names>D</given-names></name><etal/></person-group><article-title>Graft Failure Due to Noncompliance Among 628 Kidney Transplant Recipients With Long-Term Follow-Up: A Single-Center Observational Study</article-title>. <source>Transplantation</source> (<year>2014</year>) <volume>97</volume>(<issue>9</issue>):<fpage>925</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1097/01.TP.0000438199.76531.4a</pub-id><pub-id pub-id-type="pmid">24445926</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chisholm-Burns</surname><given-names>MA</given-names></name><name name-style="western"><surname>Spivey</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rehfeld</surname><given-names>R</given-names></name><name name-style="western"><surname>Zawaideh</surname><given-names>M</given-names></name><name name-style="western"><surname>Roe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gruessner</surname><given-names>R</given-names></name></person-group>. <article-title>Immunosuppressant Therapy Adherence and Graft Failure Among Pediatric Renal Transplant Recipients</article-title>. <source>Am J Transpl</source> (<year>2009</year>) <volume>9</volume>(<issue>11</issue>):<fpage>2497</fpage>&#8211;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02793.x</pub-id><pub-id pub-id-type="pmid">19681814</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spivey</surname><given-names>CA</given-names></name><name name-style="western"><surname>Chisholm&#8208;Burns</surname><given-names>MA</given-names></name><name name-style="western"><surname>Damadzadeh</surname><given-names>B</given-names></name><name name-style="western"><surname>Billheimer</surname><given-names>D</given-names></name></person-group>. <article-title>Determining the Effect of Immunosuppressant Adherence on Graft Failure Risk Among Renal Transplant Recipients</article-title>. <source>Clin Transpl</source> (<year>2014</year>) <volume>28</volume>(<issue>1</issue>):<fpage>96</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1111/ctr.12283</pub-id><pub-id pub-id-type="pmid">24329814</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loupy</surname><given-names>A</given-names></name><name name-style="western"><surname>Haas</surname><given-names>M</given-names></name><name name-style="western"><surname>Roufosse</surname><given-names>C</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>M</given-names></name><name name-style="western"><surname>Adam</surname><given-names>B</given-names></name><name name-style="western"><surname>Afrouzian</surname><given-names>M</given-names></name><etal/></person-group><article-title>The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell&#8211; and Antibody-Mediated Rejection</article-title>. <source>Am J Transpl</source> (<year>2020</year>) <volume>20</volume>(<issue>9</issue>):<fpage>2318</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.15898</pub-id><pub-id pub-id-type="pmcid">PMC7496245</pub-id><pub-id pub-id-type="pmid">32463180</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nevins</surname><given-names>TE</given-names></name><name name-style="western"><surname>Robiner</surname><given-names>WN</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>W</given-names></name></person-group>. <article-title>Predictive Patterns of Early Medication Adherence in Renal Transplantation</article-title>. <source>Transplantation</source> (<year>2014</year>) <volume>98</volume>(<issue>8</issue>):<fpage>878</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000000148</pub-id><pub-id pub-id-type="pmid">24831921</pub-id><pub-id pub-id-type="pmcid">PMC4199876</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pabst</surname><given-names>S</given-names></name><name name-style="western"><surname>Bertram</surname><given-names>A</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>T</given-names></name><name name-style="western"><surname>Schiffer</surname><given-names>M</given-names></name><name name-style="western"><surname>de Zwaan</surname><given-names>M</given-names></name></person-group>. <article-title>Physician Reported Adherence to Immunosuppressants in Renal Transplant Patients: Prevalence, Agreement, and Correlates</article-title>. <source>J Psychosom Res</source> (<year>2015</year>) <volume>79</volume>(<issue>5</issue>):<fpage>364</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychores.2015.09.001</pub-id><pub-id pub-id-type="pmid">26526310</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Geest</surname><given-names>S</given-names></name><name name-style="western"><surname>Borgermans</surname><given-names>L</given-names></name><name name-style="western"><surname>Gemoets</surname><given-names>H</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>I</given-names></name><name name-style="western"><surname>Vlaminck</surname><given-names>H</given-names></name><name name-style="western"><surname>Evers</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence, Determinants, and Consequences of Subclinical Noncompliance With Immunosuppressive Therapy in Renal Transplant Recipients</article-title>. <source>Transplantation</source> (<year>1995</year>) <volume>59</volume>(<issue>3</issue>):<fpage>340</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00007890-199502000-00006</pub-id><pub-id pub-id-type="pmid">7871562</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlaminck</surname><given-names>H</given-names></name><name name-style="western"><surname>Maes</surname><given-names>B</given-names></name><name name-style="western"><surname>Evers</surname><given-names>G</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>G</given-names></name><name name-style="western"><surname>Lerut</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prospective Study on Late Consequences of Subclinical Non-compliance With Immunosuppressive Therapy in Renal Transplant Patients</article-title>. <source>Am J Transpl</source> (<year>2004</year>) <volume>4</volume>(<issue>9</issue>):<fpage>1509</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2004.00537.x</pub-id><pub-id pub-id-type="pmid">15307839</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denhaerynck</surname><given-names>K</given-names></name><name name-style="western"><surname>Steiger</surname><given-names>J</given-names></name><name name-style="western"><surname>Bock</surname><given-names>A</given-names></name><name name-style="western"><surname>Sch&#228;fer-Keller</surname><given-names>P</given-names></name><name name-style="western"><surname>K&#246;fer</surname><given-names>S</given-names></name><name name-style="western"><surname>Thannberger</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prevalence and Risk Factors of Non-adherence With Immunosuppressive Medication in Kidney Transplant Patients</article-title>. <source>Am J Transpl</source> (<year>2007</year>) <volume>7</volume>(<issue>1</issue>):<fpage>108</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2006.01611.x</pub-id><pub-id pub-id-type="pmid">17109727</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denhaerynck</surname><given-names>K</given-names></name><name name-style="western"><surname>Burkhalter</surname><given-names>F</given-names></name><name name-style="western"><surname>Sch&#228;fer-Keller</surname><given-names>P</given-names></name><name name-style="western"><surname>Steiger</surname><given-names>J</given-names></name><name name-style="western"><surname>Bock</surname><given-names>A</given-names></name><name name-style="western"><surname>De Geest</surname><given-names>S</given-names></name></person-group>. <article-title>Clinical Consequences of Non Adherence to Immunosuppressive Medication in Kidney Transplant Patients</article-title>. <source>Transpl Int</source> (<year>2009</year>) <volume>22</volume>(<issue>4</issue>):<fpage>441</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-2277.2008.00820.x</pub-id><pub-id pub-id-type="pmid">19144090</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prezelin-Reydit</surname><given-names>M</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>V</given-names></name><name name-style="western"><surname>Caillard</surname><given-names>S</given-names></name><name name-style="western"><surname>Parissiadis</surname><given-names>A</given-names></name><name name-style="western"><surname>Etienne</surname><given-names>I</given-names></name><name name-style="western"><surname>Hau</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation</article-title>. <source>J Clin Med</source> (<year>2021</year>) <volume>10</volume>(<issue>9</issue>):<fpage>2032</fpage>. <pub-id pub-id-type="doi">10.3390/jcm10092032</pub-id><pub-id pub-id-type="pmid">34068497</pub-id><pub-id pub-id-type="pmcid">PMC8125965</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girerd</surname><given-names>S</given-names></name><name name-style="western"><surname>Schikowski</surname><given-names>J</given-names></name><name name-style="western"><surname>Girerd</surname><given-names>N</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>K</given-names></name><name name-style="western"><surname>Busby</surname><given-names>H</given-names></name><name name-style="western"><surname>Gambier</surname><given-names>N</given-names></name><etal/></person-group><article-title>Impact of Reduced Exposure to Calcineurin Inhibitors on the Development of De Novo DSA: A Cohort of Non-immunized First Kidney Graft Recipients Between 2007 and 2014</article-title>. <source>BMC Nephrol</source> (<year>2018</year>) <volume>19</volume>(<issue>1</issue>):<fpage>232</fpage>. <pub-id pub-id-type="doi">10.1186/s12882-018-1014-2</pub-id><pub-id pub-id-type="pmid">30219043</pub-id><pub-id pub-id-type="pmcid">PMC6139146</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneku</surname><given-names>H</given-names></name><name name-style="western"><surname>O&#8217;Leary</surname><given-names>JG</given-names></name><name name-style="western"><surname>Banuelos</surname><given-names>N</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>LW</given-names></name><name name-style="western"><surname>Susskind</surname><given-names>BM</given-names></name><name name-style="western"><surname>Klintmalm</surname><given-names>GB</given-names></name><etal/></person-group><article-title>De Novo Donor-specific HLA Antibodies Decrease Patient and Graft Survival in Liver Transplant Recipients</article-title>. <source>Am J Transpl</source> (<year>2013</year>) <volume>13</volume>(<issue>6</issue>):<fpage>1541</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/ajt.12212</pub-id><pub-id pub-id-type="pmcid">PMC4408873</pub-id><pub-id pub-id-type="pmid">23721554</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rush</surname><given-names>DN</given-names></name><name name-style="western"><surname>Nevins</surname><given-names>TE</given-names></name><name name-style="western"><surname>Birk</surname><given-names>PE</given-names></name><name name-style="western"><surname>Blydt-Hansen</surname><given-names>T</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>IW</given-names></name><etal/></person-group><article-title>Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development</article-title>. <source>J Am Soc Nephrol</source> (<year>2017</year>) <volume>28</volume>:<fpage>3353</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2017030287</pub-id><pub-id pub-id-type="pmid">28729289</pub-id><pub-id pub-id-type="pmcid">PMC5661295</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatault</surname><given-names>P</given-names></name><name name-style="western"><surname>Kamar</surname><given-names>N</given-names></name><name name-style="western"><surname>B&#252;chler</surname><given-names>M</given-names></name><name name-style="western"><surname>Colosio</surname><given-names>C</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>D</given-names></name><name name-style="western"><surname>Durrbach</surname><given-names>A</given-names></name><etal/></person-group><article-title>Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-specific Antibodies: A Randomized Study</article-title>. <source>Am J Transpl</source> (<year>2017</year>) <volume>17</volume>(<issue>5</issue>):<fpage>1370</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.14109</pub-id><pub-id pub-id-type="pmid">27862923</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahan</surname><given-names>BD</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M</given-names></name><name name-style="western"><surname>Urbauer</surname><given-names>DL</given-names></name><name name-style="western"><surname>Mosheim</surname><given-names>MB</given-names></name><name name-style="western"><surname>Beusterien</surname><given-names>KM</given-names></name><name name-style="western"><surname>Wood</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Low Intraindividual Variability of Cyclosporin A Exposure Reduces Chronic Rejection Incidence and Health Care Costs</article-title>. <source>J Am Soc Nephrol</source> (<year>2000</year>) <volume>11</volume>(<issue>6</issue>):<fpage>1122</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.V1161122</pub-id><pub-id pub-id-type="pmid">10820177</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiau</surname><given-names>M</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>HE</given-names></name><name name-style="western"><surname>Gjertson</surname><given-names>D</given-names></name><name name-style="western"><surname>Ettenger</surname><given-names>RB</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>EW</given-names></name></person-group>. <article-title>Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation</article-title>. <source>Transplantation</source> (<year>2011</year>) <volume>92</volume>(<issue>8</issue>):<fpage>918</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31822dc34f</pub-id><pub-id pub-id-type="pmid">21857278</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigo</surname><given-names>E</given-names></name><name name-style="western"><surname>Segundo</surname><given-names>DS</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Fresnedo</surname><given-names>G</given-names></name><name name-style="western"><surname>L&#243;pez-Hoyos</surname><given-names>M</given-names></name><name name-style="western"><surname>Benito</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-specific Antibody Development</article-title>. <source>Transplantation</source> (<year>2016</year>) <volume>100</volume>(<issue>11</issue>):<fpage>2479</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000001040</pub-id><pub-id pub-id-type="pmid">26703349</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shuker</surname><given-names>N</given-names></name><name name-style="western"><surname>Shuker</surname><given-names>L</given-names></name><name name-style="western"><surname>van Rosmalen</surname><given-names>J</given-names></name><name name-style="western"><surname>Roodnat</surname><given-names>JI</given-names></name><name name-style="western"><surname>Borra</surname><given-names>LCP</given-names></name><name name-style="western"><surname>Weimar</surname><given-names>W</given-names></name><etal/></person-group><article-title>A High Intrapatient Variability in Tacrolimus Exposure Is Associated With Poor Long-Term Outcome of Kidney Transplantation</article-title>. <source>Transpl Int</source> (<year>2016</year>) <volume>29</volume>(<issue>11</issue>):<fpage>1158</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1111/tri.12798</pub-id><pub-id pub-id-type="pmid">27188932</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>C</given-names></name><name name-style="western"><surname>Nevins</surname><given-names>TE</given-names></name><name name-style="western"><surname>Robiner</surname><given-names>WN</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>W</given-names></name><name name-style="western"><surname>Matas</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nickerson</surname><given-names>PW</given-names></name></person-group>. <article-title>The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival: Class II Epitope-Mismatch and Nonadherence</article-title>. <source>Am J Transpl</source> (<year>2015</year>) <volume>15</volume>(<issue>8</issue>):<fpage>2197</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.13341</pub-id><pub-id pub-id-type="pmid">26095765</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nevins</surname><given-names>TE</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>L</given-names></name><name name-style="western"><surname>Skeans</surname><given-names>MA</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>W</given-names></name></person-group>. <article-title>The Natural History of Azathioprine Compliance After Renal Transplantation</article-title>. <source>Kidney Int</source> (<year>2001</year>) <volume>60</volume>(<issue>4</issue>):<fpage>1565</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.2001.00961.x</pub-id><pub-id pub-id-type="pmid">11576374</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Israni</surname><given-names>AK</given-names></name><name name-style="western"><surname>Weng</surname><given-names>FL</given-names></name><name name-style="western"><surname>Cen</surname><given-names>YY</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamoun</surname><given-names>M</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>HI</given-names></name></person-group>. <article-title>Electronically Measured Adherence to Immunosuppressive Medications and Kidney Function After Deceased Donor Kidney Transplantation: Medication Adherence After Renal Transplant</article-title>. <source>Clin Transpl</source> (<year>2011</year>) <volume>25</volume>(<issue>2</issue>):<fpage>E124</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0012.2010.01340.x</pub-id><pub-id pub-id-type="pmcid">PMC3566245</pub-id><pub-id pub-id-type="pmid">20977496</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>FL</given-names></name><name name-style="western"><surname>Israni</surname><given-names>AK</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hoy</surname><given-names>T</given-names></name><name name-style="western"><surname>Gaughan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Newman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Race and Electronically Measured Adherence to Immunosuppressive Medications After Deceased Donor Renal Transplantation</article-title>. <source>J Am Soc Nephrol</source> (<year>2005</year>) <volume>16</volume>(<issue>6</issue>):<fpage>1839</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2004121059</pub-id><pub-id pub-id-type="pmid">15800121</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taber</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>JN</given-names></name><name name-style="western"><surname>Fominaya</surname><given-names>CE</given-names></name><name name-style="western"><surname>Gebregziabher</surname><given-names>M</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>TR</given-names></name><etal/></person-group><article-title>The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation</article-title>. <source>Am J Nephrol</source> (<year>2017</year>) <volume>45</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1159/000453554</pub-id><pub-id pub-id-type="pmid">27907919</pub-id><pub-id pub-id-type="pmcid">PMC5214896</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senev</surname><given-names>A</given-names></name><name name-style="western"><surname>Coemans</surname><given-names>M</given-names></name><name name-style="western"><surname>Lerut</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Sandt</surname><given-names>V</given-names></name><name name-style="western"><surname>Dani&#235;ls</surname><given-names>L</given-names></name><name name-style="western"><surname>Kuypers</surname><given-names>D</given-names></name><etal/></person-group><article-title>Histological Picture of Antibody-Mediated Rejection Without Donor-specific Anti-HLA Antibodies: Clinical Presentation and Implications for Outcome</article-title>. <source>Am J Transpl</source> (<year>2019</year>) <volume>19</volume>(<issue>3</issue>):<fpage>763</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.15074</pub-id><pub-id pub-id-type="pmid">30107078</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnaidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>C</given-names></name><name name-style="western"><surname>Jurisic</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmid-Horch</surname><given-names>B</given-names></name><name name-style="western"><surname>Ender</surname><given-names>A</given-names></name><name name-style="western"><surname>Wernet</surname><given-names>D</given-names></name></person-group>. <article-title>HLA Antibody Specification Using Single-Antigen Beads--A Technical Solution for the Prozone Effect</article-title>. <source>Transplantation</source> (<year>2011</year>) <volume>92</volume>(<issue>5</issue>):<fpage>510</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31822872dd</pub-id><pub-id pub-id-type="pmid">21869744</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visentin</surname><given-names>J</given-names></name><name name-style="western"><surname>Vigata</surname><given-names>M</given-names></name><name name-style="western"><surname>Daburon</surname><given-names>S</given-names></name><name name-style="western"><surname>Contin-Bordes</surname><given-names>C</given-names></name><name name-style="western"><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><name name-style="western"><surname>Dromer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Deciphering Complement Interference in Anti-human Leukocyte Antigen Antibody Detection With Flow Beads Assays</article-title>. <source>Transplantation</source> (<year>2014</year>) <volume>98</volume>(<issue>6</issue>):<fpage>625</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000000315</pub-id><pub-id pub-id-type="pmid">25058376</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guidicelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Visentin</surname><given-names>J</given-names></name><name name-style="western"><surname>Franchini</surname><given-names>N</given-names></name><name name-style="western"><surname>Borg</surname><given-names>C</given-names></name><name name-style="western"><surname>Merville</surname><given-names>P</given-names></name><name name-style="western"><surname>Couzi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prevalence, Distribution and Amplitude of the Complement Interference Phenomenon in Single Antigen Flow Beads Assays</article-title>. <source>HLA</source> (<year>2018</year>) <volume>91</volume>(<issue>6</issue>):<fpage>507</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/tan.13263</pub-id><pub-id pub-id-type="pmid">29604172</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leening</surname><given-names>MJG</given-names></name><name name-style="western"><surname>Vedder</surname><given-names>MM</given-names></name><name name-style="western"><surname>Witteman</surname><given-names>JCM</given-names></name><name name-style="western"><surname>Pencina</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Steyerberg</surname><given-names>EW</given-names></name></person-group>. <article-title>Net Reclassification Improvement: Computation, Interpretation, and Controversies: A Literature Review and Clinician&#8217;s Guide</article-title>. <source>Ann Intern Med</source> (<year>2014</year>) <volume>160</volume>(<issue>2</issue>):<fpage>122</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.7326/M13-1522</pub-id><pub-id pub-id-type="pmid">24592497</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koenig</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Mar&#231;ais</surname><given-names>A</given-names></name><name name-style="western"><surname>Barba</surname><given-names>T</given-names></name><name name-style="western"><surname>Mathias</surname><given-names>V</given-names></name><name name-style="western"><surname>Sicard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Missing Self Triggers NK Cell-Mediated Chronic Vascular Rejection of Solid Organ Transplants</article-title>. <source>Nat Commun</source> (<year>2019</year>) <volume>10</volume>(<issue>1</issue>):<fpage>5350</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13113-5</pub-id><pub-id pub-id-type="pmid">31767837</pub-id><pub-id pub-id-type="pmcid">PMC6877588</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebraud</surname><given-names>E</given-names></name><name name-style="western"><surname>Eloudzeri</surname><given-names>M</given-names></name><name name-style="western"><surname>Rabant</surname><given-names>M</given-names></name><name name-style="western"><surname>Lamarth&#233;e</surname><given-names>B</given-names></name><name name-style="western"><surname>Anglicheau</surname><given-names>D</given-names></name></person-group>. <article-title>Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<fpage>864730</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.864730</pub-id><pub-id pub-id-type="pmid">35392097</pub-id><pub-id pub-id-type="pmcid">PMC8980419</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>